Journal of Personalized Medicine (Nov 2023)

Exploring the Role of Biomarkers Associated with Alveolar Damage and Dysfunction in Idiopathic Pulmonary Fibrosis—A Systematic Review

  • Alexandra-Simona Zamfir,
  • Mihai Lucian Zabara,
  • Raluca Ioana Arcana,
  • Tudor Andrei Cernomaz,
  • Andreea Zabara-Antal,
  • Marius Traian Dragoș Marcu,
  • Antigona Trofor,
  • Carmen Lăcrămioara Zamfir,
  • Radu Crișan-Dabija

DOI
https://doi.org/10.3390/jpm13111607
Journal volume & issue
Vol. 13, no. 11
p. 1607

Abstract

Read online

Background: Idiopathic pulmonary fibrosis (IPF) is one of the most aggressive forms of interstitial lung diseases (ILDs), marked by an ongoing, chronic fibrotic process within the lung tissue. IPF leads to an irreversible deterioration of lung function, ultimately resulting in an increased mortality rate. Therefore, the focus has shifted towards the biomarkers that might contribute to the early diagnosis, risk assessment, prognosis, and tracking of the treatment progress, including those associated with epithelial injury. Methods: We conducted this review through a systematic search of the relevant literature using established databases such as PubMed, Scopus, and Web of Science. Selected articles were assessed, with data extracted and synthesized to provide an overview of the current understanding of the existing biomarkers for IPF. Results: Signs of epithelial cell damage hold promise as relevant biomarkers for IPF, consequently offering valuable support in its clinical care. Their global and standardized utilization remains limited due to a lack of comprehensive information of their implications in IPF. Conclusions: Recognizing the aggressive nature of IPF among interstitial lung diseases and its profound impact on lung function and mortality, the exploration of biomarkers becomes pivotal for early diagnosis, risk assessment, prognostic evaluation, and therapy monitoring.

Keywords